Comprehensive hospital drug monitoring (CHDM): Adverse skin reactions, a 20-year survey

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 4, 1997, Pages 388-393

  Hunziker, Th ^a,e   Kunzi U P ^b   Braunschweig, S ^c   Zehnder, D ^d   Hoigne R ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Foundation CHDM Berne St Gallen   (Switzerland)

^c State Hospital St Gallen   (Switzerland)

^d Spital Netz Bern   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

adverse skin reactions; comprehensive hospital drug monitoring; exposure time; maculopapular exanthema; reaction time; urticaria; vasculitis

Indexed keywords

AMINOPENICILLIN; CORTICOSTEROID; CYTOSTATIC AGENT; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM; TUBERCULOSTATIC AGENT;

ACNE; ARTICLE; DRUG ERUPTION; DRUG EXPOSURE; DRUG MONITORING; ERYTHEMA MULTIFORME; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PAPULE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; REACTION TIME; SKIN MANIFESTATION; URTICARIA; VASCULITIS;

EID: 0030956850     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb01017.x     Document Type: Article

References (25)

1. Hoigné R, Stocker F, Middleton P. Epidemiology of drug allergy, drug monitoring. In: de Weck AL, Bundgaard H, editors. Allergic reactions to drugs. Handbook of experimental pharmacology. Vol. 63. Berlin: Springer-Verlag, 1983:187-205.
2. Shear NH. Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 1990;126:94-7.
3. Hoigné R, D'Andrea Jaeger M, Wymann R, et al. Time pattern of allergic reactions to drugs. In: Weber E, Lawson DH, Hoigné R, editors. Risk factors for adverse drug reactions. Agents Actions Suppl, Vol. 29. Basel: Birkhäuser-Verlag, 1990;39-57.
4. WHO Collaborating Center for International Drug Monitoring, Uppsala, Sweden; edition 4th quarter, 1988.
5. Hoigné R, Hunziker T, Künzi UP, et al. Risikofaktoren und epidemiologische Aspekte unerwünschter Arzneimittelwirkungen unter besonderer Berücksichtigung der allergischen und pseudo-allergischen Reaktionen. Allergologie 1995;18:320-6.
6. Arndt KA, Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1976;235:918-22.
7. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15483 consecutive inpatients, 1975 to 1982. JAMA 1986;256:3358-63.
8. Hoigné R, Sonntag MR, Zoppi M, Hess T, Maibach R, Fritschy D. Occurrence of exanthemas in relation to amino-penicillin preparations and allopurinol [Letter]. N Engl J Med 1987;316:1217.
9. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED). Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Dermatology 1993;186:164-9.
10. Kaiser U, Sollberger J, Hoigné R, Wymann R, Fritschy D, Maibach R. Haut-Nebenwirkungen unter nicht-steroidalen Analgetika-Entzündungshemmern und sogenannten leichten Analgetika. Schweiz Med Wochenschr 1987;117:1966-70.
11. Sonntag MR, Zoppi M, Fritschy D, et al. Exantheme unter häufig angewandten Antibiotika und antibakteriellen Chemotherapeutika (Penicilline, speziell Aminopenicilline, Cephalosporine und Cotrimoxazol) sowie Allopurinol. Schweiz Med Wochenschr 1986;116:142-5.
12. Stern RS, Bigby M. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. JAMA 1984;252:1433-7.
13. Stubb S, Heikkilä H, Kauppinen K. Cutaneous reactions to drugs: a series of in-patients during a five-year period. Acta Derm Venereol (Stockh) 1994;74:289-91.
14. Swanbeck G, Dahlberg E. Cutaneous drug reactions. An attempt at quantitative estimation. Arch Dermatol Res 1992;284:215-18.
15. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;10:1272-85.
16. Bergoend H, Löffler A, Amar R, Maleville J. Réactions cutanées survenues au cours de la prophylaxie de masse de la méningite cérébro-spinale par un sulfamide long-retard. Ann Dermatol Syph 1968;95:481-90.
17. Roujeau J-C, Guillaume J-C, Fabre J-P, Penso D, Fléchet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
18. Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
19. Chan H-L, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-7.
20. Hutchinson A, Lane A. Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol 1989;42:5-16.
21. Pere JC, Begaud B, Haramburu F, Albin H. Computerized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther 1986;40:451-61.
22. Roujeau J-C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
23. Hoigné R, Hunziker T. Editorial: "Palpable purpura". Schweiz Med Wochenschr 1992;122:1271-4.
24. Friedman GD, Collen MF, Harris LE, Van Brunt EE, Davis LS. Experience in monitoring drug reactions in outpatients: the Kaiser-Permanente Drug Monitoring System. JAMA 1971;217:567-72.
25. Rawlins MD. Clinical pharmacology. Adverse reactions to drugs. BMJ 1981;282:974-6.